Amgen Faces Growth Headwinds from Biosimilars Despite Strong Financials
PILLAR DIAGNOSTIC // WEEK 07
“A binding biosimilar and pricing headwind is set to cap Amgen’s top-line growth despite upbeat guidance and bullish sentiment; with no clear mechanical sell-off yet, true repricing is likely when upcoming pricing data and patient-volume trends expose the competitive ceiling.”
Proposed action
Cautious – avoid initiating new longs or consider trimming existing positions ahead of near-term data and pricing catalysts.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
Amgen scaled revenue to $36.75 billion in 2025 with double-digit revenue and EPS growth, guided $37.0 billion–$38.4 billion for 2026 and projects roughly $37.4 billion by 2028, while delivering broad-based volume gains across key products and generating strong free cash flow to sustain stable dividends and fund new investments.
THE MAP
Structure & constraints
Disease awareness initiatives and new coding criteria are broadening diagnosed patient populations, but legacy product revenues face pressure from biosimilar entries and pricing challenges; competition spans major players in oncology and immunology, with strategic partnerships and targeted trial designs shaping market access and uptake.
THE MOOD
Consensus & positioning
Health Care and IT names are drawing investor enthusiasm as cheap turnaround stories like Amgen, Merck, Bristol Myers Squibb, and Gilead circulate with expectations of double-digit EPS growth and bullish rating updates, though a handful of warning signs inject some caution.